Low-grade gliomas (LGG) are the most frequent pediatric tumors associated with epilepsy. Molecular sequencing analyses have defined the genomic landscape of these tumors leading to the use of targeted therapies, which have proven to be efficacious. Ongoing clinical trials are testing the incorporation of these drugs, especially in unresectable LGG that progress after standard treatment. Nevertheless, this strategy is not extended in the field of tumor-induced epilepsy. We present a patient with drug-resistant epilepsy secondary to a BRAF V600E-mutated ganglioglioma treated with dabrafenib who showed a dramatic radiological and clinical response with marked improvement in her quality of life.

Diffuse intrinsic pontine glioma (DIPG) is the most frequent brainstem tumor in children. All therapeutic efforts are palliative, being focal irradiation the only therapy capable of reducing temporarily tumor volume. The vast majority of patients succumb to their disease during the first 2 years after diagnosis usually due to local progression. At first relapse, focal re-irradiation has shown to provide clinical and radiologic benefits. There are no reports of craniospinal irradiation (CSI) as a rescue regimen when progression is local and disseminated. We report a patient treated with CSI at metastatic progression showing clinical and radiological response with good tolerance.